Filing Details
- Accession Number:
- 0000950142-10-000393
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-03-08 12:00:00
- Reporting Period:
- 2010-03-04
- Filing Date:
- 2010-03-08
- Accepted Time:
- 2010-03-08 20:52:01
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1401923 | Map Pharmaceuticals Inc. | MAPP | Pharmaceutical Preparations (2834) | 200507047 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 900203 | George Soros | 888 Seventh Ave 31St Flr New York NY 10106 | No | No | Yes | No | |
| 1029160 | Soros Fund Management Llc | 888 Seventh Avenue 31St Floor New York NY 10106 | No | No | Yes | No | |
| 1387524 | Robert Soros | C/O Soros Fund Management Llc 888 Seventh Avenue, 31St Floor New York NY 10106 | No | No | Yes | No | |
| 1387590 | Allan T Jonathan Soros | C/O Soros Fund Management Llc 888 Seventh Avenue, 31St Floor New York NY 10106 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2010-03-04 | 677 | $14.15 | 3,128,834 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Disposition | 2010-03-04 | 97 | $14.09 | 3,128,834 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Disposition | 2010-03-04 | 3,061 | $14.15 | 3,128,834 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Disposition | 2010-03-04 | 2,503 | $14.09 | 3,128,834 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Disposition | 2010-03-05 | 4,616 | $13.95 | 2,928,446 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Disposition | 2010-03-05 | 6,524 | $13.95 | 2,928,446 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Disposition | 2010-03-05 | 20,872 | $13.95 | 2,928,446 | No | 4 | S | Indirect | See Footnotes |
| Common Stock | Disposition | 2010-03-05 | 168,376 | $13.95 | 2,928,446 | No | 4 | S | Indirect | See Footnotes |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
| No | 4 | S | Indirect | See Footnotes |
Footnotes
- The price shown in Column 4 is a weighted average sale price. The price range for the sales is $14.00 to $14.23. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- All of the securities reported herein are held for the account of Perseus-Soros BioPharmaceutical Fund, LP ("Perseus-Soros"), Perseus-Soros Partners, LLC ("Perseus-Soros Partners"), the general partner of Perseus-Soros, SFM Participation, L.P ("SFM Participation"), a managing member of Perseus-Soros Partners, as well as Biotech Management Partners, LLC ("Biotech Management Partners") and Quantum Industrial Partners, LDC ("QIP").
- Perseus-Soros Partners is the general partner of Perseus-Soros. SFM Participation is a managing member of Biotech Management Partners and Perseus-Soros Partners. SFM AH, LLC, a Delaware limited liability company ("SFM AH"), is the general partner of SFM Participation. The sole managing member of SFM AH is SFM LLC. SFM LLC also serves as the principal investment manager to QIP. Mr. George Soros ("Mr. Soros") serves as Chairman of SFM LLC, Mr. Robert Soros ("Robert Soros") serves as Deputy Chairman of SFM LLC and Mr. Jonathan Soros ("Jonathan Soros") serves as President and Deputy Chairman of SFM LLC.
- Represents 677 shares of the Issuer's Common Stock sold by Perseus-Soros Partners. After the sale Perseus-Soros Partners owns directly 4,616 shares of the Issuer's Common Stock.
- Represents 97 shares of the Issuer's Common Stock sold by SFM Participation. After the sale SFM Participation owns directly 10,313 shares of the Issuer's Common Stock.
- Represents 3,061 shares of the Issuer's Common Stock sold by Biotech Management Partners. After the sale Biotech Management Partners owns directly 20,872 shares of the Issuer's Common Stock.
- Represents 2,503 shares of the Issuer's Common Stock sold by QIP. After the sale QIP owns directly 266,158 shares of the Issuer's Common Stock.
- The price shown in Column 4 is a weighted average sale price. The price range for the sales is $13.70 to $14.39. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- Represents 4,616 shares of the Issuer's Common Stock sold by Perseus-Soros Partners. After the sale Perseus-Soros Partners directly owns no shares of the Issuer's Common Stock.
- Represents 6,524 shares of the Issuer's Common Stock sold by SFM Participation. After the sale SFM Participation owns directly 3,789 shares of the Issuer's Common Stock.
- Represents 20,872 shares of the Issuer's Common Stock sold by Biotech Management Partners. After the sale Biotech Management Partners directly owns no shares of the Issuer's Common Stock.
- Represents 168,376 shares of the Issuer's Common Stock sold by QIP. After the sale QIP owns directly 97,782 shares of the Issuer's Common Stock.
Billionaire Hedge Funds
